{
  "id": "52b2f1724003448f5500000b",
  "type": "yesno",
  "question": "Is JTV519 (K201) a potential drug for the prevention of arrhythmias?",
  "ideal_answer": "Yes, JTV519 has antiarrhythmic properties.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/20581784",
    "http://www.ncbi.nlm.nih.gov/pubmed/15584870",
    "http://www.ncbi.nlm.nih.gov/pubmed/16825580",
    "http://www.ncbi.nlm.nih.gov/pubmed/21291389",
    "http://www.ncbi.nlm.nih.gov/pubmed/22001562",
    "http://www.ncbi.nlm.nih.gov/pubmed/15073377",
    "http://www.ncbi.nlm.nih.gov/pubmed/22563249",
    "http://www.ncbi.nlm.nih.gov/pubmed/20080988",
    "http://www.ncbi.nlm.nih.gov/pubmed/17644079",
    "http://www.ncbi.nlm.nih.gov/pubmed/23144205",
    "http://www.ncbi.nlm.nih.gov/pubmed/17994112",
    "http://www.ncbi.nlm.nih.gov/pubmed/11090108",
    "http://www.ncbi.nlm.nih.gov/pubmed/12890053",
    "http://www.ncbi.nlm.nih.gov/pubmed/16672364",
    "http://www.ncbi.nlm.nih.gov/pubmed/16185151"
  ],
  "snippets": [
    {
      "text": "We compared the suppressive effect of K201 (JTV519), a multiple-channel blocker and cardiac ryanodine receptor-calcium release channel (RyR2) stabilizer, with that of diltiazem, a Ca(2+ )channel blocker, in 2 studies of isoproterenol-induced (n = 30) and ischemic-reperfusion-induced VAs (n = 38) in rats. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23144205",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "After administration of isoproterenol under Ca(2+) loading, fatal VA frequently occurred in the vehicle (9 of 10 animals, 90%) and diltiazem (8 of 10, 80%) groups, and K201 significantly suppressed the incidences of arrhythmia and mortality (2 of 10, 20%). In the reperfusion study, the incidence and the time until occurrence of reperfusion-induced VA and mortality were significantly suppressed in the K201 (2 of 15 animals, 13%) and diltiazem (1 of 9 animals, 11%) groups compared to the vehicle group (8 of 14 animals, 57%). ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23144205",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "K201 markedly suppressed both the isoproterenol-induced and the reperfusion-induced VAs, whereas diltiazem did not suppress the isoproterenol-induced VA.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23144205",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "JTV519 (K201) is a newly developed 1,4-benzothiazepine drug with antiarrhythmic and cardioprotective properties. It appears to be very effective in not only preventing but also in reversing the characteristic myocardial changes and preventing lethal arrhythmias.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22563249",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The novel antiarrhythmic drug K201 (4-[3-{1-(4-benzyl)piperidinyl}propionyl]-7-methoxy-2,3,4,5-tetrahydro-1,4-benzothiazepine monohydrochloride) is currently in development for treatment of atrial fibrillation. K201 not only controls intracellular calcium release by the ryanodine receptors, but also possesses a ventricular action that might predispose to torsade de pointes arrhythmias. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22001562",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The RyR is currently used as a therapeutic target in malignant hyperthermia where dantrolene is effective and to relieve ventricular arrhythmia, with the use of JTV519 and flecainide.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21291389",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Finally, KN-3 and JTV519, two compounds that stabilize RyR2 in the closed state, prevent the induction of triggered activity and suppress the inducibility of sustained AF. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/20581784",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "JTV-519 greatly reduced the frequency of ouabain-induced arrhythmogenic events.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/20080988",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Stabilization of RyR2 by JTV-519 effectively reduces these triggered arrhythmias.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/20080988",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "These findings may reveal the anti-arrhythmic potential of K201.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/17994112",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The preferential ryanodine receptor stabilizer (K201) possesses antiarrhythmic effects through calcium regulation. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/17994112",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The drug K201 (JTV-519) increases inotropy and suppresses arrhythmias in failing hearts, but the effects of K201 on normal hearts is unknown. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/17644079",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "K201 fails to prevent DADs in RyR2(R4496C+/-) myocytes and ventricular arrhythmias in RyR2(R4496C+/-) mice",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/16825580",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In vivo administration of K201 failed to prevent induction of polymorphic ventricular tachycardia (VT) in RyR2(R4496C+/-) mice.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/16825580",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The 1,4-benzothiazepine JTV519, which increases the binding affinity of calstabin-2 for RyR2, inhibited the diastolic SR Ca2+ leak, monophasic action potential alternans and triggered arrhythmias.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/16672364",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In arrhythmias, the calstabin2 stabiliser JTV519 did not prevent arrhythmias in calstabin2-/- mice, but reduced the arrhythmias in calstabin2+/- mice, illustrating the antiarrhythmic potential of stabilising calstablin2. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/16185151",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In three models of arrhythmias, the calstabin2 stabiliser JTV519 did not prevent arrhythmias in calstabin2(-/-) mice, but reduced the arrhythmias in calstabin2(+/-) mice, illustrating the antiarrhythmic potential of stabilising calstabin2. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/15584870",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "A derivative of 1,4-benzothiazepine (JTV519) increased the affinity of calstabin2 for RyR2, which stabilized the closed state of RyR2 and prevented the Ca2+ leak that triggers arrhythmias. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/15073377",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "JTV-519 had significant protective effects on atrial fibrillation in the canine sterile pericarditis model, mainly by increasing effective refractory period, suggesting that it may have potential as a novel antiarrhythmic agent for atrial fibrillation.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/12890053",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "JTV-519 significantly decreased the mean number of sustained atrial fibrillation episodes (from 4.2 +/- 2.9 to 0 +/- 0, P < 0.01). ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/12890053",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "We conclude that JTV-519 can exert antiarrhythmic effects against AF by inhibiting repolarizing K(+) currents. The drug may be useful for the treatment of AF in patients with ischaemic heart disease.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/11090108",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [
    "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D000889"
  ],
  "exact_answer": "Yes"
}